The global sales of blood product will reach nearly $42.6 billion in 2021
LONDON, June 5, 2017 /PRNewswire/ -- The global sales of blood products reached $31.8 billion in 2015 and $33.5 billion in 2016.
The market is expected to grow at a five-year compound annual growth rate (CAGR) of 4.9% from 2016 to 2021, reaching nearly $42.6 billion in 2021.
Blood therapeutics as a segment reached $27.2 billion in 2016 and should reach $35.0 billion by 2021, with a CAGR of 5.2%.
Blood-screening and blood-typing products a s a segment reached $3.8 billion in 2016 and should reach nearly $4.9 billion by 2021, with a CAGR of 5.2%.
Introduction
Study Goals and Objectives
The goals of this study on the blood industry are to describe and analyze the current markets for blood products, blood tests and blood-processing equipment, as well as present important new developments affecting every aspect of this industry. In addition, the report provides an analysis of market-value forecast through 2021 in constant dollars, as well as profiles of companies in the industry. The study covers the major aspects of blood and plasma collection/transfusion, including autologous donations, apheresis, fractionation, blood salvage and stem cells. The major plasma products such as coagulation factors, human serum albumin and immunoglobulins are analyzed as well. The scope and character of the blood-testing segment is changing constantly so the impact of new products, technologies and equipment is analyzed. The study also covers international developments in blood banking and related areas, as well as research and patents that will affect the future of the blood industry.
Reasons for Doing This Study
A safe and adequate blood supply is essential to the practice of modern medicine. The U.S. blood industry is safe and blood supplies are usually adequate. Current efforts in the industry are focused on increasing the blood supply in other world markets and improving education efforts for a safe and sufficient blood supply globally. New advances, particularly in the area of automation, have enhanced both safety and blood availability, and it is the purpose of this study to detail these advances and their impact on the blood industry. There have been advances in technology that have allowed more red blood cells to be obtained from fewer donors. Technological advances have also allowed for greater economies and increased safety in the blood supply.
Contribution of the Study and Intended Audience
With its broad scope and in-depth analyses, this study will prove to be a valuable resource to anyone involved with or interested in the blood industry. This study will provide information on these areas:
- The structure and current market size of the blood industry with forecasts through 2021.
- Blood-usage patterns and trends.
- Government and regulatory controls.
- The impact of disease on the blood industry.
- Major players and their relative market share and market potential.
- Current product lines and examination of newly emerging products and technologies.
- The state of the international markets for various blood and blood-related products.
- Newly issued patents relating to blood- and disease-screening technologies.
Since the study provides business and technical information of a timely nature, it will prove valuable to a variety of readers, including industry executives, managers and planners, researchers, industry analysts and investors. The projections, forecasts and trend analyses found in this report provide readers with
the necessary data and information for careful decision-making.
Scope and Format
This study encompasses the wide range of products and services that comprise the global blood-industry marketplace. The U.S. market, the largest in the world, provides the primary market breakdown with supplemental information given for other regions. The focus of the report is two-fold: first, blood for donation and the components and derived products from this blood and plasma, and second, products used to provide and support collection, processing and transfusion. Excluded from consideration are the clinical blood tests for diseases and conditions not involved in managing blood and plasma products.
Methodology and Information Sources
Data for this study were collected using both primary and secondary data research techniques. Literature searches of various sources including scientific, medical and business publications and databases were conducted. On-line databases and government sources were consulted as well. Extensive interviews were conducted with industry personnel, scientists, professional and trade organizations, government agency personnel, observers, scientists and industry professionals. The collected data were analyzed to determine specific findings and forecasts. Once these forecasts were obtained, they were validated with industry experts. Since some segments of this report are not measured routinely, BCC Research derived estimates from a variety of analogous sources.
Whenever market estimates are derived, they are fully noted. It should be pointed out that, while many factors were considered in constructing different models, the projections are ultimately speculative. As a composite of the opinions and assessments of interviewees, the author, other analysts and secondary
sources, these projections represent something of a consensus. However, all recognize that the relative importance of selected factors could change at any time with new technologies and new products, and thus change the direction of the market projections. All forecasts use constant 2014 U.S. dollars.
Download the full report: https://www.reportbuyer.com/product/1498888/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article